The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Tumor delivery of macromolecular drugs based on the EPR effect
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationAmphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027
Self-citationExploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
Self-citationVascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Self-citationChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Maeda, H., Sawa, T., & Konno, T. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00309-1 · Cited by 925
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Bae, Y., Nishiyama, N., Fukushima, S., Koyama, H., Yasuhiro, M., & Kataoka, K. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0498166 · Cited by 742
Transport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Greish, K. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701539584 · Cited by 600
Pharmacokinetics of stealth versus conventional liposomes: effect of dose
Allen, T. M., & Hansen, C. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90201-i · Cited by 579
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
“SMART” Drug Delivery Systems: Double-Targeted pH-Responsive Pharmaceutical Nanocarriers
Sawant, R. M., Hurley, J. P., Salmaso, S., Kale, A., Tolcheva, E., Levchenko, T. S., & Torchilin, V. P. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060080h · Cited by 540
Self-citationWhich polymers can make nanoparticulate drug carriers long-circulating?
Torchilin, V. P., & Trubetskoy, V. S. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00022-y · Cited by 480
Self-citationPegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Gabizon, A. A. (2001) · Cancer Investigation · doi:10.1081/cnv-100103136 · Cited by 458
Polymeric micelles for drug delivery
Aliabadi, H. M., & Lavasanifar, A. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.139 · Cited by 446
Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430
Medical Applications of Liposomes
(1998) · Elsevier eBooks · doi:10.1016/b978-0-444-82917-7.x5000-5 · Cited by 416
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Stereocomplex Block Copolymer Micelles: Core−Shell Nanostructures with Enhanced Stability
Kang, N., Perron, M.-È., Prud'homme, R. E., Zhang, Y., Gaucher, G., & Leroux, J.-C. (2005) · Nano Letters · doi:10.1021/nl048037v · Cited by 335
Core-cross-linked polymeric micelles as paclitaxel carriers
Shuai, X., Merdan, T., Schaper, A. K., Xi, F., & Kissel, T. (2004) · Bioconjugate Chemistry · doi:10.1021/bc034113u · Cited by 333
Liposome circulation time and tumor targeting: implications for cancer chemotherapy
Gabizon, A. A. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00030-b · Cited by 255
Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., & Harashima, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.008 · Cited by 254
Abuchowski, A., Kazo, G. M., Cr, V., Es, T. V., Kafkewitz, D., Ml, N., At, V., & Ff, D. (1984) · PubMed · Cited by 249
Polymer-coated long-circulating microparticulate pharmaceuticals
Torchilin, V. P. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006831 · Cited by 235
Self-citationKale, A. A., & Torchilin, V. P. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060228x · Cited by 228
Self-citationWater soluble polymers in tumor targeted delivery
Kopeček, J., Kopečková, P., Minko, T., Lu, Z.-R., & Peterson, C. M. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00330-3 · Cited by 227
Fang, J., Sawa, T., & Maeda, H. (2005) · Advances in Experimental Medicine and Biology · doi:10.1007/0-306-47932-x_2 · Cited by 221
Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium
Torchilin, V. P., Klibanov, A. L., Huang, L., O'Donnell, S., Nossiff, N. D., & Khaw, B. A. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.9.1612296 · Cited by 216
Self-citationMulticenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma
Wollina, U., Dummer, R., Brockmeyer, N. H., Konrad, H., Busch, J. ‐., Kaatz, M., Knopf, B., Koch, H., & Hauschild, A. (2003) · Cancer · doi:10.1002/cncr.11593 · Cited by 214
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., & Gabizon, A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990701)86:1<72::aid-cncr12>3.0.co;2-1 · Cited by 213
Tanaka, T., Shiramoto, S., Miyashita, M., Fujishima, Y., & Kaneo, Y. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.050 · Cited by 206
Zalipsky, S., Qazen, M., Walker, J. A., Mullah, N., Quinn, Y. P., & Huang, S. K. (1999) · Bioconjugate Chemistry · doi:10.1021/bc990031n · Cited by 198
Nagamitsu, A., Greish, K., & Maeda, H. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp074 · Cited by 180
Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application
Seki, T., Fang, J., & Maeda, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01323.x · Cited by 179
ElBayoumi, T. A., & Torchilin, V. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2392 · Cited by 170
Self-citationYasuda, H., Yamaya, M., Nakayama, K., Sasaki, T., Ebihara, S., Kanda, A., Asada, M., Inoue, D., Suzuki, T., Okazaki, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0436 · Cited by 170
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes
Hatakeyama, H., Akita, H., Ishida, E., Hashimoto, K., Kobayashi, H., Aoki, T., Yasuda, J., Obata, K., Kikuchi, H., Ishida, T., et al. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.037 · Cited by 165
Jeong, J. H., Kim, S. W., & Park, T. G. (2003) · Bioconjugate Chemistry · doi:10.1021/bc025632k · Cited by 161
Kale, A. A., & Torchilin, V. P. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701498203 · Cited by 159
Self-citationCancer-Targeted Polymeric Drugs
Luo, Y., & Prestwich, G. (2002) · Current Cancer Drug Targets · doi:10.2174/1568009023333836 · Cited by 147
Asselin, B. L. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4811-9_69 · Cited by 142
The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.
Asselin, B. L. (1999) · PubMed · Cited by 129
Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*
Skubitz, K. M. (2003) · Cancer Investigation · doi:10.1081/cnv-120016412 · Cited by 122
Yasuda, H., Nakayama, K., Watanabe, M., Suzuki, S., Fuji, H., Okinaga, S., Kanda, A., Zayasu, K., Sasaki, T., Asada, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1124 · Cited by 120
Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study
Bukowski, R. M., Ernstoff, M. S., Gore, M. E., Nemunaitis, J. J., Amato, R. J., Gupta, S. K., & Tendler, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.051 · Cited by 117
Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
O’Shaughnessy, J. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.037 · Cited by 117
Perez, A., Domenech, G. H., Frankel, C., & Vogel, C. L. (2002) · Cancer Investigation · doi:10.1081/cnv-120014883 · Cited by 114
Lavasanifar, A. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00537-5 · Cited by 97
Yuan, X., Harada, A., Yamasaki, Y., & Kataoka, K. (2005) · Langmuir · doi:10.1021/la0488811 · Cited by 96
The mechanism of liposome accumulation in infarction
Palmer, T. N., Caride, V. J., Caldecourt, M. A., Twickler, J., & Abdullah, V. S. (1984) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(84)90258-7 · Cited by 95
Yagi, N., Manabe, I., Tottori, T., Ishihara, A., Ogata, F., Kim, J. H., Nishimura, S., Fujiu, K., Oishi, Y., Itaka, K., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3945 · Cited by 92
Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art
Bondı̀, M. L., & Craparo, E. F. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903362410 · Cited by 86
Ligand‐Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues
Thomas, M., Kularatne, S. A., Qi, L., Kleindl, P. J., Leamon, C. P., Hansen, M. J., & Low, P. S. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04977.x · Cited by 85
Biomedical Aspects of Drug Targeting
(2002) · Springer eBooks · doi:10.1007/978-1-4757-4627-3 · Cited by 80
Moghimi, S. M. (2006) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152006778699130 · Cited by 76
Kano, A., Moriyama, K., Yamano, T., Nakamura, I., Shimada, N., & Maruyama, A. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.007 · Cited by 69
Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Modi, S., Jain, J. P., Domb, A. J., & Kumar, N. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779026272 · Cited by 69
ElBayoumi, T. A., & Torchilin, V. P. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8001528 · Cited by 68
Self-citationLiposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer
Schwonzen, M., Kurbacher, C. M., & Mallmann, P. K. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200010000-00002 · Cited by 66
Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00216-7 · Cited by 65
Maeda, H. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.002 · Cited by 64
Johnston, S. R. D., & Gore, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00329-x · Cited by 60
Role of Block Copolymer Nanoconstructs in Cancer Therapy
Upadhyay, K. K., Agrawal, H., Upadhyay, C., Schatz, C., Meins, J. L., Misra, A. R., & Lecommandoux, S. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i2.20 · Cited by 52
Lavignac, N., Lazenby, M., Franchini, J., Ferruti, P., & Duncan, R. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.06.001 · Cited by 50
Immobilized Enzymes in Medicine
Torchilin, V. P. (1991) · Progress in clinical biochemistry and medicine · doi:10.1007/978-3-642-75821-8 · Cited by 46
Self-citationHPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer
Peterson, C. M., Shiah, J.-G., Sun, Y., Kopečková, P., Minko, T., Straight, R. C., & Kopeček, J. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47932-x_7 · Cited by 45
Specific Targets in Tumor Tissue for the Delivery of Therapeutic Genes
Günther, M., Wagner, E., & Ogris, M. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053174855 · Cited by 37
Schmidinger, M., Wenzel, C.-K., Locker, G. J., Muehlbacher, F., Steininger, R., Gnant, M., Crevenna, R., & Budinsky, A. C. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2149 · Cited by 35
Delivery of Protein and Peptide Drugs in Cancer
Torchilin, V. P. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860948039 · Cited by 34
Self-citationEndosomes as a route for drug delivery in the real world
Sheff, D. R. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.11.005 · Cited by 33
Gonçalvès, A., Braud, A. C., Viret, F., Genre, D., Gravis, G., Tarpin, C., Giovannini, M. F., Maraninchi, D., & Viens, P. (2003) · PubMed · Cited by 30
Enhanced Permeability and Retention (EPR) Efect: Basis for Drug Targeting to Tumor
Maeda, H. (2002) · Springer eBooks · doi:10.1007/978-1-4757-4627-3_11 · Cited by 26
Enhanced Permeability and Retention (EPR) Effect and Tumor-Selective Delivery of Anticancer Drugs
Greish, K. F., Iyer, A. K., Fang, J. Q., Kawasuji, M., & Maeda, H. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860948039_0003 · Cited by 26
Cited by
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Metadata
- Authors
- Torchilin, V.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 63
- Issue
- 3
- Pages
- 131-135
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1985241728
- Cited by
- 2,032
- References
- 83
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.